Jazz Pharmaceuticals
Search results
GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.
May 5, 2021 · Jazz Pharmaceuticals completes the acquisition of GW Pharmaceuticals, a leader in cannabinoid-based prescription medicines, including Epidiolex for epilepsy. The transaction is expected to deliver substantial shareholder value and diversify Jazz's pipeline and commercial portfolio.
Feb 3, 2021 · Jazz Pharmaceuticals and GW Pharmaceuticals announce a definitive agreement for Jazz to acquire GW for $7.2 billion, creating a global biopharma leader in neuroscience and oncology. GW's lead product, Epidiolex, is a cannabidiol medicine for epilepsy, and GW has a pipeline of cannabinoid candidates for other indications.
Aug 10, 2021 · The MHRA has granted a new indication for GW's cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), a rare genetic disorder. The approval is based on a positive Phase 3 study showing a 49% reduction in seizure frequency compared to placebo.
Feb 3, 2021 · Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals, a British pioneer in cannabis-based medicines, in a $7.2bn cash-and-stock deal that will expand the US drugmaker’s neuroscience...
- Ortenca Aliaj
Feb 16, 2021 · The company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox...
Feb 16, 2021 · GW reports strong revenue and Epidiolex sales growth, and advances nabiximols and other pipeline programs. GW also announces agreement to be acquired by Jazz Pharmaceuticals for $220 per share.
